Guselkumab (Tremfya)
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Induction: Guselkumab (Tremfya) 200 mg/20 mL vial of sterile solution administered through IV infusion. Maintenance: Guselkumab (Tremfya) 100 mg/1 mL pre-filled syringe, 100 mg/1 mL patient-controlled injector, 200 mg/2 mL pre-filled syringe, and 200 mg/2 mL pre-filled pen administered by subcutaneous injection. Indication: For the treatment of adult patients with moderately to severely active ulcerative colitis.
Fields of Study & Subjects
Inflammatory Bowel Disease
Health Systems
Economic Evaluations
Quality of Life
Pharmaceutical Economics and Policy
Publication details
- Journal / source
- Canadian Journal of Health Technologies
- Volume
- 6
- Issue
- 3
- Publication date
- 27 March 2026
- Language
- EN